APR March 2024 - 23

« FORMULATION AND DEVELOPMENT
8.
Conclusion
While there is risk associated with using an instrument and associated
software without proper audit trails and for which the calculations
cannot be independently verified, the previous summary allows
that risk to be considered low in lieu of the wide applicability of the
entire AUC software suite in research and industry. IT departments
have a set of tools that mitigate software limitations, and the four
eyes principle (where two individuals are involved in the review and
approval of critical processes or data) can be applied in instances
where such tools are not available. To further ensure that instrument
and software performance issues do not impact any GMP data,
method-performance-specific controls can be established during
method qualification and/or validation. The summary of all control
data acquired can be used to establish a range for the reportable
parameters that the control/reference standard has to meet as part
of the method's system suitability. For example, in the analysis of AAV
capsids, the percent empty and full capsid values for the control as
well as the associated sedimentation coefficients must meet the
method specific system suitability ranges for an analysis to be valid.
This enables the detection of software-induced inaccuracies.
By the time this article is published, new developments may
streamline GMP adaptations of AUC. For example, Alexander E.
Yarawsky et al. recently published a paper under the guidance of Lake
N. Paul that describes a new program, " BASIS, " which allows for 21 CFR
Part 11-compliant data handling and data analysis using the SEDFIT
analysis software.26
We are looking forward to learning about BASIS
and other future developments in the rapidly evolving and exciting
area of AUC.
References
1.
2.
3.
4.
5.
18.
9.
10.
11.
12.
13.
Svedberg T, Rinde H (1924) The ultracentrifuge: a new instrument for the determination of
size and distribution of size of particles in amicrosopic colloids. J Am Chem Soc 46:2677-
2693
Uchimaya S, Arisaka F, Stafford W, Laue T (eds) (2016) Analytical ultracentrifugation:
instrumentation, software and applications. Springer, Tokyo
Schuck P, Zao H, Brautigam C, Ghirlando R (2016) Basic principles of analytical
ultracentrifugation. CRC Press, Boca Raton
Patel T, Winzor DJ, Scott DJ (2016) Analytical ultracentrifugation: a versatile tool for
characterisation of macromolecular complexes in solution. Methods 95:56-61
Lamm O. Die Differentialgleichung der Ultrazentrifugierung (1929) Ark Mat Astr Fys.
21B(2):1-4
Edwards, G. B., Muthurajan, U. M., Bowerman, S., & Luger, K. (2020) Analytical
ultracentrifugation (AUC): An overview of the application of fluorescence and absorbance
AUC to the study of biological macromolecules. Current Protocols in Molecular Biology 133,
e131. doi: 10.1002/cpmb.131
14.
SEDFIT, accessible at https://sedfitsedphat.nibib.nih.gov/software/default.aspx.
More
information regarding SEDFIT may be found in P. Schuck (2000) Size distribution analysis
of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation
modeling. Biophysical Journal 78:1606-1619.
15. Moving analytical ultracentrifugation software to a good manufacturing practices (GMP)
environment; A. Savelyev et al., PLOS Computational Biology 19 June 2020. https://doi.
org/10.1371/journal.pcbi.1007942
16.
GUSSI, accessible at https://www.utsouthwestern.edu/labs/mbr/software/.
information regarding GUSSI may be found in Brautigam, C.
17.
More
A., Calculations and
publication-quality illustrations for analytical ultracentrifugation data, Methods Enzymol.
562, 109-134 (2015). "
Brautigam, C. A. (2015) Calculations and publication-quality illustrations for analytical
ultracentrifugation data, Methods Enzymol. 562:109-134.
Peter Schuck, Samuel C. To, and Huaying Zhao (2023) An Automated Interface for
Sedimentation Velocity Analysis in SEDFIT. PLOS Computational Biology, https://doi.
org/10.1371/journal.pcbi.1011454
The Death of Jesse Gelsinger, 20 Years Later; M. Rinde 04 June 2019 Science History
Institute. Accessed August 7, 2023.
death-of-jesse-gelsinger-20-years-later
https://www.sciencehistory.org/distillations/theChemistry,
Manufacturing, and Controls Changes to an Approved Application: Certain
899 Biological Products; Guidance for Industry, June 2021, 900. https://www.fda.gov/
media/109615/download.
Human Gene Therapy for Neurodegenerative Diseases; Guidance for Industry, September
2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/
human-gene-therapy-neurodegenerative-diseases.
Briefing Document on Toxicity Risks of AAV Vectors for Gene Therapy (GT); FDA Cellular,
Tissue, and Gene Therapies Advisory Committee (CTGTAC) Meeting #70, September 2 3,
2021.
P. Wunderli et.al., Viral Vector API Characterization of Product-Related Impurities,
Pharmaceutical Technology ‐ Regulatory Sourcebook, pp.52-58, October 2020 ‐ PharmTech
‐ (https://www.e-digitaleditions.com/i/1302985-pharmtech-regulatory-sourcebookoctober/51?)
6.
7.
Charge
Detection Mass Spectrometry: Analysis of Gene Therapy Vectors, M.F. Jarrold, LCGC
Supplements 40(9): 14-18, 2022. https://doi.org/10.56530/lcgc.na.wh5987h4
Analytical methods for process and product characterization of recombinant adenoassociated
virus-based gene therapies; A.L. Gimpel at el., Molecular Therapy: Methods &
Clinical Development Vol. 20 March 2021. http://creativecommons.org/licenses/by-ncnd/4.0/
19.
Garcia de la Torre J, Hernandez Cifre JG, Diez Pena AI (2018) Prediction and analysis of
analytical ultracentrifugation experiments for heterogeneous macromolecules and
nanoparticles based on Brownian dynamics simulation. Eur Biophys J 47:845-854
20.
21.
Valderama OJ and Nischang I (2021) Reincarnation of the Analytical Ultracentrifuge:
Emerging Opportunities for Nanomedicine. Anal. Chem. 93: 15805−15815
Murano T, Usami K, Ishii K, Torisu T, and Uchiyama S (2021) Comprehensive Size
Distribution and Composition Analysis of Adeno-Associated Virus Vector Multiwavelength
Sedimentation Velocity Analytical Ultracentrifugation. J Pharm Sci 110:3375-3384
22.
Zhao H, Brautigam CA, Ghirlando R and Schuck P (February 2013) Current methods in
Sedimentation Velocity and Sedimentation Equilibrium Analytical Ultracentrifugation.
Curr Protoc Sci. 0-20. doi:10.1002/0471140864.ps2012s71
23.
Burnham B, Nass S, Kong E, Mattingly ME, Woodcock D, Song A, Wadsworth S, Cheng
SH, Scaria A, and O'Riordan CR (2015) Analytical Ultracentrifugation as an Approach to
Characterize Recombinant Adeno-Associated Viral Vectors. Human Gene Therapy Methods
26(6): 228-242. DOI: 10.1089/hgtb.2015.048
24.
Khasa H, Kilby G, Chen X, and Wang C (2021) Analytical band centrifugation for the
separation and quantification of empty and full AAV particles. Molecular Therapy: Methods
& Clinical Development. 21:585-591
25. World
26.
Intellectual Property Organization
(2016) Analytical
Ultracentrifugation
Characterization of Recombinant Viral Particles. WO 2016/118520 A1
Yarawsky, A.E., Gough, E.S., Zai-Rose, V. et al. BASIS: BioAnalysis SEDFIT Integrated
Software for cGMP Analysis of SV-AUC Data, Eur Biophys J (2024)
www.americanpharmaceuticalreview.com |
| 23
for
»

http://www.americanpharmaceuticalreview.com

APR March 2024

Table of Contents for the Digital Edition of APR March 2024

Message from the Editor
Editorial Advisory Board
BIOPHARMACEUTICALS - Getting to GMP-Quality Biotherapeutics From Today’s Bench-Scale Continuous Manufacturing Systems: A Gap Analysis
MICROBIOLOGY - Critical Behavioral Attributes and the Application of COM-B Framework in Aseptic Processing
FORMULATION AND DEVELOPMENT - Use of AUC in AAV Analysis in a GMP Setting
FORMULATION AND DEVELOPMENT - Precision Medicine in Clinical Trials: A Statistical Perspective
An Interview with Dan Smithey, PhD President & CEO, Serán
FORMULATION AND DEVELOPMENT - Still Early Days for AI in Drug Discovery...Says Who?
QC Corner - Enhancing Material and Equipment Availability in Production Isolators
BIOPHARMACEUTICALS - Technologies for Aseptic Filling: The Choice is Clear
Vendor Viewpoint - Data Integrity and Rapid Micro Methods: Transforming to a Modern Microbiology Lab
MICROBIOLOGY - Bacterial Spore Formers in Disinfectant Efficacy Testing
Partner Perspective - Nanoparticle Technologies: Enablers for Ocular Drug Delivery
DRUG DELIVERY - Your Nails and You
DRUG DEVELOPMENT - Battling Exorbitance: High Costs in Sickle Cell Gene Therapies and the Imperative of Global Patient Registries for Equity
FORMULATION AND DEVELOPMENT - How Pharma Companies Are Solving Regulatory Challenges with AI-based Technology
Event Preview - CPHI North America
Event Preview - Excipient World 2024
P.I.N. Points
Advertiser's Index
APR March 2024 - CoverTip01
APR March 2024 - CoverTip02
APR March 2024 - Cover1
APR March 2024 - Cover2
APR March 2024 - 1
APR March 2024 - 2
APR March 2024 - 3
APR March 2024 - 4
APR March 2024 - 5
APR March 2024 - Message from the Editor
APR March 2024 - Editorial Advisory Board
APR March 2024 - BIOPHARMACEUTICALS - Getting to GMP-Quality Biotherapeutics From Today’s Bench-Scale Continuous Manufacturing Systems: A Gap Analysis
APR March 2024 - 9
APR March 2024 - 10
APR March 2024 - 11
APR March 2024 - 12
APR March 2024 - 13
APR March 2024 - MICROBIOLOGY - Critical Behavioral Attributes and the Application of COM-B Framework in Aseptic Processing
APR March 2024 - 15
APR March 2024 - 16
APR March 2024 - 17
APR March 2024 - 18
APR March 2024 - FORMULATION AND DEVELOPMENT - Use of AUC in AAV Analysis in a GMP Setting
APR March 2024 - 20
APR March 2024 - 21
APR March 2024 - 22
APR March 2024 - 23
APR March 2024 - FORMULATION AND DEVELOPMENT - Precision Medicine in Clinical Trials: A Statistical Perspective
APR March 2024 - 25
APR March 2024 - 26
APR March 2024 - 27
APR March 2024 - An Interview with Dan Smithey, PhD President & CEO, Serán
APR March 2024 - 29
APR March 2024 - 30
APR March 2024 - FORMULATION AND DEVELOPMENT - Still Early Days for AI in Drug Discovery...Says Who?
APR March 2024 - 32
APR March 2024 - 33
APR March 2024 - QC Corner - Enhancing Material and Equipment Availability in Production Isolators
APR March 2024 - 35
APR March 2024 - BIOPHARMACEUTICALS - Technologies for Aseptic Filling: The Choice is Clear
APR March 2024 - 37
APR March 2024 - 38
APR March 2024 - 39
APR March 2024 - Vendor Viewpoint - Data Integrity and Rapid Micro Methods: Transforming to a Modern Microbiology Lab
APR March 2024 - 41
APR March 2024 - MICROBIOLOGY - Bacterial Spore Formers in Disinfectant Efficacy Testing
APR March 2024 - 43
APR March 2024 - Partner Perspective - Nanoparticle Technologies: Enablers for Ocular Drug Delivery
APR March 2024 - 45
APR March 2024 - 46
APR March 2024 - 47
APR March 2024 - DRUG DELIVERY - Your Nails and You
APR March 2024 - 49
APR March 2024 - 50
APR March 2024 - 51
APR March 2024 - DRUG DEVELOPMENT - Battling Exorbitance: High Costs in Sickle Cell Gene Therapies and the Imperative of Global Patient Registries for Equity
APR March 2024 - 53
APR March 2024 - 54
APR March 2024 - 55
APR March 2024 - FORMULATION AND DEVELOPMENT - How Pharma Companies Are Solving Regulatory Challenges with AI-based Technology
APR March 2024 - 57
APR March 2024 - Event Preview - CPHI North America
APR March 2024 - 59
APR March 2024 - Event Preview - Excipient World 2024
APR March 2024 - 61
APR March 2024 - P.I.N. Points
APR March 2024 - 63
APR March 2024 - Advertiser's Index
APR March 2024 - Cover3
APR March 2024 - Cover4
https://www.nxtbookmedia.com